Future COVID shots should target JN.1, KP.2 subvariants --US FDA staff

Primary tabs

Future COVID shots should target JN.1, KP.2 subvariants --US FDA staff

Mon, 2024-06-03 21:12 — mike kraft

COVID shots should target JN.1, KP.2 subvariants in 2024-25 campaign, US FDA staff says Vaccine makers should consider targeting one of the currently dominant JN.1 variants and JN.1-derived subvariants such as KP.2 as they develop COVID-19 shots for the 2024-2025 campaign, the U.S. Food and Drug Administration's staff said on Monday. Reuters Reuters

The FDA reviewers said since the difference between JN.1 and newer subvariants such as KP.2 subvariants is not much, it is possible that vaccines developed against JN.1 may adequately protect against KP.2.

But, the reviewers added that further evolution of the virus could take it away from JN.1, so vaccine makers may need to consider updating their vaccine to the currently predominant variant....

Country / Region Tags:

General Topic Tags: